Notice Number: NOT-DA-12-001

Key Dates
Release Date: October 13, 2011

Issued by
National Institute on Drug Abuse (NIDA)

Purpose

The purpose of this Notice is to clarify that multi-PD(s)PI(s) are not allowed for PAR-11-269, Pre-Application for the 2012 NIDA Translational Avant-Garde Award for Medication Development for the Treatment of Substance-Use Disorders (X02), https://grants.nih.gov/grants/guide/pa-files/PAR-11-269.html. 

The Eligible Individuals section should read:

Eligible Individuals (Program Director(s)/Principal Investigator(s)

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

Applications with multiple PD(s)/PI(s) are not allowed.

Under Scored Review Criteria the Investigator section should read as follows:

Scored Review Criteria

Investigator(s)    

Are the PD(s)/PI(s), collaborators, and other researchers well suited to the project? If Early Stage Investigators or New Investigators, or in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project? In particular, is there sufficient evidence of the investigator’s expertise in drug discovery and development and/or translational research, and is there demonstrated ability by the investigator to devote at least 51% or 6.1 person months of his/her research effort to activities supported by this Award?    

All other aspects of the FOA remain the same.  

Inquiries

Please direct all inquiries to:

Nora Chiang, PhD
Division of Pharmacotherapies and Medical Consequences of Drug Abuse
Chemistry and Pharmaceutics Branch Research
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-5280
Email: [email protected]